
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3437478/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. International Journal of Infectious Diseases, 2013, 17, e1056-e1059.	3.3	269
2	Crimean-Congo Hemorrhagic Fever in Turkey. Emerging Infectious Diseases, 2004, 10, 1379-1384.	4.3	229
3	Role of platelets in immune system and inflammation. Porto Biomedical Journal, 2017, 2, 311-314.	1.0	68
4	Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. Journal of Experimental and Clinical Cancer Research, 2008, 27, 11.	8.6	64
5	Breakthrough Trichosporon asahii Fungemia in Neutropenic Patient with Acute Leukemia while Receiving Caspofungin. Infection, 2008, 36, 68-70.	4.7	63
6	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Oncology, 2017, 28, 2496-2502.	1.2	60
7	A Case of Acute Colitis with Severe Rectal Bleeding in a Patient with Chronic Myeloid Leukemia after Dasatinib Use. Acta Haematologica, 2010, 123, 205-206.	1.4	50
8	HLA-DRB1 allele distribution and its relation to rheumatoid arthritis in eastern Black Sea Turkish population. Rheumatology International, 2012, 32, 1003-1007.	3.0	27
9	Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever. Journal of Clinical Virology, 2008, 42, 415-417.	3.1	26
10	Is SCUBE 1 a new biomarker for gastric cancer?. Cancer Biomarkers, 2012, 11, 191-195.	1.7	23
11	MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. American Journal of Hematology, 2004, 76, 40-43.	4.1	21
12	Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia. Journal of the National Medical Association, 2017, 109, 23-27.	0.8	20
13	The Relation of Lymphomaand Hepatitis B Virus/Hepatitis C Virus Infections in the Region of East Black Sea, Turkey. Tumori, 2007, 93, 536-539.	1.1	19
14	<i>Rosa canina</i> Extract has Antiproliferative and Proapoptotic Effects on Human Lung and Prostate Cancer Cells. Nutrition and Cancer, 2020, 72, 273-282.	2.0	19
15	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576.	1.8	19
16	Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever. Journal of Infection, 2007, 55, 184-187.	3.3	16
17	The Effect of Dexmedetomidine on Oxidative Stress during Pneumoperitoneum. BioMed Research International, 2014, 2014, 1-5.	1.9	16
18	Raoultella ornithinolytica causing fatal sepsis. Brazilian Journal of Infectious Diseases, 2015, 19, 230-231.	0.6	16

#	Article	IF	CITATIONS
19	The use of Ankaferd blood stopper in a patient with Glanzmann's thrombasthenia with gingival bleeding. Blood Coagulation and Fibrinolysis, 2010, 21, 382-383.	1.0	15
20	Synthesis of Fe and Cu metal complexes derived from â€~SNS' Pincer type ligands and their efficient catalyst precursors for the chemical fixation of \$\$hbox {CO}_{2}\$\$ CO 2. Journal of Chemical Sciences, 2019, 131, 1.	1.5	14
21	MTHFR C677T Polymorphism and Its Relationship to Myocardial Infarction in the Eastern Black Sea Region of Turkey. Archives of Medical Research, 2011, 42, 709-712.	3.3	13
22	Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Cytotherapy, 2013, 15, 352-361.	0.7	13
23	Treatment related changes in antifibrinolytic activity in patients with polycythemia vera. Hematology, 2010, 15, 391-396.	1.5	12
24	Relation of HLA-A, -B, -DRB1 Alleles and Haplotypes in Patients with Acute Leukemia: A Case Control Study. Archives of Medical Research, 2011, 42, 305-310.	3.3	12
25	Brentuximab vedotin consolidation therapy after autologous stemâ€cell transplantation in patients with highâ€risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology, 2021, 39, 498-505.	1.7	12
26	Change of coagulation parameters after double plateletpheresis. Transfusion and Apheresis Science, 2007, 37, 161-163.	1.0	11
27	Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 91-92.	1.5	11
28	Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study. Chemotherapy, 2018, 63, 207-213.	1.6	11
29	The expression of LMO2 protein in acute B-cell and myeloid leukemia. Hematology, 2010, 15, 132-134.	1.5	10
30	The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia. Turkish Journal of Haematology, 2016, 33, 135-140.	0.5	10
31	Synthesis of novel chiral metal complexes derived from chiral thiosemicarbazide ligands as potential antioxidant agents. Chirality, 2019, 31, 434-444.	2.6	10
32	Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome. Advances in Clinical and Experimental Medicine, 2018, 27, 1567-1572.	1.4	10
33	The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori, 2007, 93, 536-9.	1.1	10
34	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. Turkish Journal of Haematology, 2019, 36, 230-237.	0.5	8
35	Effect of Early or Delayed Administration of Warfarin with Heparin on Thrombosis in Pulmonary Thromboembolism. Medical Principles and Practice, 2011, 20, 181-186.	2.4	7
36	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels. Clinical and Experimental Hypertension, 2013, 35, 134-140.	1.3	7

#	Article	IF	CITATIONS
37	C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease. Hematology, 2014, 19, 213-216.	1.5	7
38	Repression of oxidative phosphorylation sensitizes leukemia cell lines to cytarabine. Hematology, 2018, 23, 330-336.	1.5	7
39	High levels of endothelial progenitor cells and circulating endothelial cells in patients with Behçet's disease and their relationship to disease activity. Anais Brasileiros De Dermatologia, 2019, 94, 320-326.	1.1	7
40	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e474-e484.	0.4	7
41	Pd (II) complexes bearing "SNS―pincerâ€ŧype thioether ligands: Application as catalysts in the synthesis of vitamin K <sub>3</sub> . Applied Organometallic Chemistry, 2022, 36, e6467.	3.5	7
42	Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 329-330.	1.5	6
43	Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)?. International Journal of Hematology, 2009, 90, 273-274.	1.6	6
44	Familial Hodgkin's Lymphoma from the Perspective of HLA. Internal Medicine, 2010, 49, 607-610.	0.7	6
45	The Role of Fibrinolytic and Antifibrinolytic Activities in the Pathophysiology of HELLP Syndrome. Hypertension in Pregnancy, 2011, 30, 275-286.	1.1	6
46	Associations of HLAâ€DRB1 alleles with antiâ€citrullinated protein antibodyâ€positive and antiâ€citrullinated protein antibodyâ€negative rheumatoid arthritis in northern east part of Turkey. International Journal of Rheumatic Diseases, 2012, 15, 538-545.	1.9	6
47	The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. Cancer Biomarkers, 2015, 15, 559-565.	1.7	6
48	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	1.8	6
49	The importance of risk factors for the prediction of patients with invasive pulmonary aspergillosis. Revista Da Associação Médica Brasileira, 2017, 63, 764-770.	0.7	6
50	The Turkish experience with therapeutic plasma exchange: A national survey. Transfusion and Apheresis Science, 2019, 58, 287-292.	1.0	6
51	Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4). Turkish Journal of Haematology, 2015, 32, 100-117.	0.5	6
52	Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. Hematology, 2009, 14, 220-223.	1.5	5
53	Can ischemia-modified albumin be a valuable indicator of tissue ischemia in polycythemia vera?. Hematology, 2010, 15, 151-156.	1.5	5
54	The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene, 2016, 586, 263-267.	2.2	5

#	Article	IF	CITATIONS
55	Higher Thrombin-Antithrombin III Complex Levels May Indicate Severe Acute Pancreatitis. Digestive Diseases, 2018, 36, 244-251.	1.9	5
56	Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia. Central-European Journal of Immunology, 2018, 43, 276-280.	1.2	5
57	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology, 2018, 23, 771-777.	1.5	5
58	Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study. Turkish Journal of Haematology, 2021, 38, 101-110.	0.5	5
59	Association of Gastrointestinal Stromal Tumor and Acute Myeloid Leukemia Preceded by Myelodysplastic Syndrome with Refractory Anemia. Tumori, 2009, 95, 240-242.	1.1	4
60	The changes in complete blood count in thyroid cancer patients treated with radioactive iodine ablation therapy. Turkish Journal of Haematology, 2010, 27, 269-274.	0.5	4
61	Treatment of tumor lysis syndrome with the highest known uric acid level. Renal Failure, 2010, 32, 895-898.	2.1	4
62	Multiple myeloma with multilobated plasma cell nuclei. Turkish Journal of Haematology, 2011, 28, 158-159.	0.5	4
63	Anti-carbonic anhydrase antibodies in iron deficiency anemia. Hematology, 2015, 20, 363-367.	1.5	4
64	Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia. Turkish Journal of Haematology, 2017, 34, 307-313.	0.5	4
65	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology, 2022, 15, 97-106.	2.2	4
66	Effects of Interferon-α-2a on Th3 Cytokine Response in Multiple Myeloma Patients. Tumori, 2004, 90, 387-389.	1.1	3
67	The assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine. Turkish Journal of Haematology, 2021, 38, 306-313.	0.5	2
68	Effects of interferon-alpha-2a on Th3 cytokine response in multiple myeloma patients. Tumori, 2004, 90, 387-9.	1.1	2
69	FDG-PET in mantle cell lymphoma involving skin. Turkish Journal of Haematology, 2010, 27, 324-5.	0.5	1
70	Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia. Wspolczesna Onkologia, 2013, 1, 83-87.	1.4	1
71	The role of hepatocyte growth factor in the differentiation of dendritic cells from peripheral blood monocytes. Journal of King Abdulaziz University, Islamic Economics, 2007, 28, 688-95.	1.1	1
72	The association of bladder myeloid sarcoma and unclassified myelodysplastic/myeloproliferative disease. Turkish Journal of Haematology, 2009, 26, 90-2.	0.5	1

#	Article	IF	CITATIONS
73	Endothelial Progenitor Cell Levels and Extent of Post-prandial Lipemic Response. Frontiers in Nutrition, 2022, 9, 822131.	3.7	1
74	Effect of High-Dose Medroxyprogesterone Acetate on Tumor Necrosis Factor-Alpha Release in Patients with Chemotherapy-Induced Neutropenia. Journal of Chemotherapy, 1997, 9, 377-381.	1.5	0
75	Aggressive Multiple Myeloma with Unusual Morphology. Turkish Journal of Haematology, 2014, 31, 437-438.	0.5	0
76	Poststreptococcal Glomerulonephritis in a Patient with Essential Thrombocytosis. Journal of Nippon Medical School, 2015, 82, 59-63.	0.9	0
77	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. Turkish Journal of Medical Sciences, 2021, 51, 1033-1042.	0.9	0
78	A Rare Plasma Cell Dyscrasias: IgM Myeloma: Case Report. Turkiye Klinikleri Journal of Medical Sciences, 2010, 30, 1727-1731.	0.1	0
79	Long-term Treatment Outcome of Patients with Hairy Cell Leukemia: A Single-Center Experience. Turkiye Klinikleri Journal of Medical Sciences, 2018, 38, 236-240.	0.1	0
80	Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study. Blood, 2019, 134, 5476-5476.	1.4	0
81	Ekstranodal Diffüz Büyük B Hücreli Lenfomada Bcl-2 ve Myc Ekspresyon Birlikteliğinin Tedavi Yanıtı Prognoza Etkisinin Geriye Dönük Olarak Değerlendirilmesi. LLM Dergi, 2020, 3, 92-100.	ve 0.0	0
82	Diffüz Büyük B Hücreli Lenfomada Prognostik Skorlama Sistemlerinin Karşılaştırılması. LLM D 27-33.	ergi, 2021 0:0	1,5,
83	Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis. American Journal of Blood Research, 2021, 11, 279-285.	0.6	0
84	Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective. Turkish Journal of Haematology, 2021, 38, 344-346.	0.5	0
85	An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy. Blood, 2021, 138, 4730-4730.	1.4	0
86	‡oklu İlaca Dirençli Akut Graft Versus Host Hastalığında Ruksolitinib. LLM Dergi, 2022, 6, 1−8.	0.0	0
87	Cytotoxic effects of water and ethanolic extracts of Turkish propolis on human laryngeal epidermoid carcinoma cell lines. Food and Health, 2022, 8, 218-228.	0.4	0
88	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology, 0, , .	1.6	0